Factor V Leiden

Last updated: November 01, 2022

Factor V Leiden

Watch later

Watch later

Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Cranial nerves
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Hypertension: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Myocardial infarction
Patent ductus arteriosus
Pericarditis and pericardial effusion
Peripheral artery disease
Pleural effusion
Pneumonia
Pulmonary edema
Restrictive lung diseases
Shock
Stroke volume, ejection fraction, and cardiac output
Tetralogy of Fallot
Diabetes mellitus: Pathology review
Abnormal uterine bleeding: Clinical
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Primary adrenal insufficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Testosterone
Thyroid hormones
Benign prostatic hyperplasia
Anemia of chronic disease
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Hypocalcemia
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Vaccinations
Acute cholecystitis
Acute pancreatitis
Acute pyelonephritis
Alcohol-associated liver disease
Appendicitis
Autoimmune hepatitis
Biliary colic
Bowel obstruction
Celiac disease
Chronic cholecystitis
Chronic pyelonephritis
Chronic pancreatitis
Cirrhosis
Congenital disorders: Clinical
Crohn disease
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome
Lower urinary tract infection
Nephrotic syndromes: Pathology review
Peptic ulcer
Renal failure: Pathology review
Ulcerative colitis
Urinary tract infections: Pathology review
Viral hepatitis
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Skin cancer
Varicella zoster virus
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid use disorder
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Pediatric infectious rashes: Clinical
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus

Transcript

Watch video only

Factor V Leiden is a disorder where blood clots form more easily due to a mutation in a clotting protein called factor V. Factor V Leiden is the most common hypercoagulable disorder in people of caucasian descent, and was named after the town Leiden in Holland, where the disease was first described.

Now, Factor V Leiden is a hemostasis disorder.

Hemostasis is the process where blood flow is stopped after there’s damage to a blood vessel, and it has two steps.

Primary hemostasis involves the formation of a platelet plug at the site of injury, and secondary hemostasis involves the coagulation cascade, where several clotting factors come into play to form a fibrin mesh over the platelet plug to reinforce it - forming a blood clot.

Hemostasis can be both stimulated, and inhibited by several factors.

One way to stimulate hemostasis is with thrombin, or factor II, which increases platelet activation, and cleaves several factors involved in secondary hemostasis to their active form.

So one way to inhibit hemostasis is actually to inhibit thrombin.

This happens with the help of anticoagulant proteins like protein C. Protein C is a vitamin K dependent circulating plasma protein produced in the liver along with a cofactor called protein S.

Both protein C and S interact with a protein called thrombomodulin, which is on the surface of intact endothelial cells that line our blood vessels.

So, let’s say you cut your finger and now a blood clot has formed.

When there’s a lot of thrombin around a damaged blood vessel, excess thrombin binds to thrombomodulin and it can no longer participate in the coagulation cascade.

So in a sense, the undamaged cells help ensure that the coagulation process is limited to the injury site.

Furthermore, the thrombin-thrombomodulin complex binds to protein C. Protein S then joins the party, forming a complex that includes protein C, protein S, and thrombin-thrombomodulin. Protein S binding to this complex activates the proteolytic site of protein C which then cleaves and inactivates active factor V, which is a cofactor for factor X in the common pathway of the coagulation cascade, as well as factor VIII, which is a cofactor for factor IX in the intrinsic pathway of the coagulation cascade.

This slows down coagulation. What is more, the factor V degradation product also binds to this complex and further enhances its ability to cleave more active factor V and active factor VIII, further limiting coagulation.

So anticoagulation prevents clots from growing too large and blocking blood flow to tissues supplied by the vessel.

It also prevents clots from getting so big that small parts of the growing clot break off in the form of emboli.

So with Factor V Leiden, both active factor V, termed Va and inactivated factor V become resistant to cleavage by activated protein C because of a mutation that results in a misshapen cleavage site.

So when activated protein C, protein S, and the thrombin-thrombomodulin complex binds and tries to cleave factor Va or inactivate factor V, it can't because the normal cleavage site isn’t there!

And when factor V can’t be inactivated, you guessed it - coagulation doesn’t slow down, so there’s increased blood clot formation.

Usually, these clots develop in the deep veins of the lower limbs, like the popliteal and femoral veins, causing a venous thromboembolism, where small parts of the clot can break off and travel to other organs, like the lungs, the brain or the liver, cutting off blood flow to those organs.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  3. "Harrison's Principles of Internal Medicine" McGraw-Hill (2004)
  4. "Factor V Leiden" Radiol Technol (2019)
  5. "Factor V Leiden thrombophilia" Genet Med (2011)
  6. "Factor V Leiden" The Journal of Perinatal & Neonatal Nursing (2003)
  7. "Diagnosis and management of<i>factor V Leiden</i>" Expert Review of Hematology (2016)